Cambridge Investment Research Advisors’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $217K | Buy |
23,172
+3,446
| +17% | +$32.3K | ﹤0.01% | 3287 |
|
|
2025
Q1 | $140K | Buy |
19,726
+6,722
| +52% | +$47.7K | ﹤0.01% | 3291 |
|
|
2024
Q4 | $152K | Buy |
13,004
+2,607
| +25% | +$30.5K | ﹤0.01% | 3249 |
|
|
2024
Q3 | $214K | Buy |
+10,397
| New | +$214K | ﹤0.01% | 3095 |
|
|
2023
Q3 | – | Sell |
-5,560
| Closed | -$227K | – | 3230 |
|
|
2023
Q2 | $227K | Buy |
+5,560
| New | +$227K | ﹤0.01% | 2771 |
|
|
2022
Q4 | – | Sell |
-4,591
| Closed | -$257K | – | 3181 |
|
|
2022
Q3 | $257K | Buy |
4,591
+123
| +3% | +$6.89K | ﹤0.01% | 2493 |
|
|
2022
Q2 | $231K | Sell |
4,468
-430
| -9% | -$22.2K | ﹤0.01% | 2598 |
|
|
2022
Q1 | $356K | Sell |
4,898
-863
| -15% | -$62.7K | ﹤0.01% | 2396 |
|
|
2021
Q4 | $681K | Sell |
5,761
-5,233
| -48% | -$619K | ﹤0.01% | 1857 |
|
|
2021
Q3 | $1.48M | Buy |
10,994
+1,164
| +12% | +$156K | 0.01% | 1260 |
|
|
2021
Q2 | $1.59M | Buy |
+9,830
| New | +$1.59M | 0.01% | 1236 |
|